Healthcare | September 30, 2025
Gleneagles Hospital Mumbai and Medtronic host conclave on hub & spoke model and AI in healthcare
The Hub & Spoke model is designed to extend advanced medical care to a wider community
The Hub & Spoke model is designed to extend advanced medical care to a wider community
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Subscribe To Our Newsletter & Stay Updated
